MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
11.07
+0.04 (0.36%)
Nov 20, 2026, 4:00 PM EST - Market closed
MLTX Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -273.48 | -227.32 | -118.94 | -36.01 | -49.97 | -64.37 |
Depreciation & Amortization | 3.4 | 2.62 | 1.39 | 0.37 | 0.16 | 0.01 |
Asset Writedown & Restructuring Costs | - | - | - | - | - | 5.82 |
Stock-Based Compensation | 22.34 | 12.9 | 7.28 | 7.11 | 9.65 | 10.86 |
Other Operating Activities | 0.49 | -4.08 | -2.53 | -8.03 | -14.16 | 0.09 |
Change in Accounts Receivable | -2.03 | -2.03 | -1.79 | -0.84 | -0.07 | -0.18 |
Change in Accounts Payable | -11.43 | 20.56 | 7.16 | 1.58 | -1.31 | 1.88 |
Change in Other Net Operating Assets | 16.68 | 1.34 | -9.15 | -6.96 | -0.2 | 3.68 |
Operating Cash Flow | -244.04 | -196.01 | -116.59 | -42.78 | -55.89 | -42.21 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | -0.04 | -0.52 | -0.28 | -0.02 | -0.06 |
Investment in Securities | -88.26 | 203.03 | -205.08 | -24.9 | -32.32 | - |
Investing Cash Flow | -88.26 | 202.99 | -205.6 | -25.18 | -32.34 | -0.06 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 73.02 | - | - | - | - |
Total Debt Issued | 24.47 | 73.02 | - | - | - | 18 |
Short-Term Debt Repaid | - | - | - | - | -15 | - |
Total Debt Repaid | - | - | - | - | -15 | - |
Net Debt Issued (Repaid) | 24.47 | 73.02 | - | - | -15 | 18 |
Issuance of Common Stock | 341.67 | 72.98 | 52.78 | 482.45 | 0.05 | 0.13 |
Repurchase of Common Stock | - | - | - | - | - | -0.01 |
Other Financing Activities | -1.5 | - | -1.47 | -2.75 | 134.65 | - |
Financing Cash Flow | 364.63 | 146 | 51.31 | 479.7 | 119.69 | 51.92 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -0.39 | 1.11 | 0.13 | -0.08 | 0.01 | 0 |
Net Cash Flow | 31.95 | 154.09 | -270.74 | 411.66 | 31.47 | 9.65 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -244.04 | -196.04 | -117.11 | -43.06 | -55.91 | -42.27 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -3.27 | -3.04 | -1.86 | -0.88 | -1.90 | -5.39 |
Levered Free Cash Flow | -146.75 | -120.38 | -92.06 | -24.14 | -32.23 | - |
Unlevered Free Cash Flow | -140.78 | -115.85 | -92.06 | -24.14 | -32.23 | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 8.3 | 5.06 | - | - | - | - |
Cash Income Tax Paid | 0.8 | 0.8 | 0.15 | 0.04 | 0 | - |
Change in Working Capital | 3.22 | 19.88 | -3.78 | -6.22 | -1.58 | 5.38 |